Evaluation of ischemia modified albumin levels in major depression patients



Ischemia modified albumin, Major depressive disorder, Mood disorders, Oxidative stress, Biomarker


Aim: Depression is an important public health problem, which has been associated with an antioxidant defense system. Ischemia-modified albumin (IMA) is a new biomarker that measures ischemia. The aim of this study was to evaluate IMA levels as a new parameter related to oxidative stress in patients with major depressive disorder (MDD).

Methods: This cross-sectional case-control study included 59 patients aged between 18-65 years who were admitted to our psychiatry outpatient clinic between June 2018-December 2018, diagnosed with MDD and had not used psychotropic drugs for 3 months. In addition, 59 age and sex matched healthy controls were included in the study. Serum IMA and albumin levels were measured in blood samples taken from each patient and from control groups. Hamilton Depression Rating Scale (HDRS) was applied to the subjects to evaluate the depression level. 

Results: Among the MDD group, 27 patients (45.8%) were male and 32 (54.2%) were female. The number of males and females in the control group were 29 (49%) and 30 (51%). Mean ages of the patients in MDD and control groups were 39.40 (12.20) and 38.67 (9.29) years, respectively. No statistically significant difference was found between the groups in terms of age and gender (P=0.942 and P=0.714, respectively). The mean IMA level of MDD and control group patients were 0.84 (0.39) and 0.82 (0.30), respectively; the difference was statistically significant (P<0.001). There was also a statistically significant difference between the albumin levels of the two groups (P=0.01). Correlation analysis showed a positive correlation between serum IMA levels and HDRS scores (r=0.235, P=0.008).

Conclusion: In our study, IMA levels of MDD patients were significantly higher than that of the control group. This result may be an indicator of increased oxidative stress in patients with depression. There is little data in the literature evaluating IMA levels in psychiatric disorders.


Download data is not yet available.


Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, et al. Prevalence and treatment of mental disorders, 1990 to 2003. New England Journal of Medicine. 2005;352(24):2515-23.

Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology. 2011;36(12):2375-94.

Sözeri Varma G. Major Depresif Bozuklukta Nöroinflamatuvar Hipotez. Psikiyatride Güncel Yaklaşımlar. 2014;6(1):1-9.

Çelik Helvacı F, Hocaoğlu Ç. Major depresif bozukluk tanımı, etyolojisi ve epidemiyolojisi: bir gözden geçirme. Çağdaş Tıp Dergisi. 2016;6(1):51-66.

Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med. 2011;49(2):177-84.

Gulpamuk B, Tekin K, Sonmez K, Inanc M, Neselioglu S, Erel O, Yilmazbas P. The significance of thiol/disulfide homeostasis and ischemia-modified albumin levels to assess the oxidative stress in patients with different stages of diabetes mellitus. Scandinavian journal of clinical and laboratory investigation. 2018;78(1-2):136-42.

Çevik M. U, Yücel Y, Arıkanoğlu A, Varol S, Akıl E, Yüksel H, et al. Multipl sklerozlu hastalarda serum prolidaz ve iskemi modifiye albümin düzeyleri. Journal of Clinical and Experimental Investigations. 2012;3(4):518-20.

Ustun Y, Ustun YE, Ozturk O, Alanbay I, Yaman H. Ischemia-modified albumin as an oxidative stress marker in preeclampsia. The Journal of Maternal-Fetal and Neonatal Medicine. 2011;24(3):418–21.

Marta MMF, Duarte A, João BT, Rocha AB, Rafael N, Moresco C, et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clinical Biochemistry. 2009;42:666-71.

Kaefer Michelle K, Sílvia JP, José AM De Carvalho, Dievan B Da Silva, Aline MB, et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clinical Biochemistry. 2010;43:450-4.

Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. J Emerg Med. 2000;19:311–5.

Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Archiv General Psychiatr. 1988;45:742-7.

Akdemir A, Örsel SD, Dağ İ, Türkçapar H, İşcan N, Özbay H. Hamilton depresyon derecelendirme ölçeğinin geçerliliği-güvenilirliği ve klinikte kullanımı. Psikiyatri, Psikoloji ve Psikofarmakoloji Dergisi. 1996;4:251-9.

Vavakova M, Durackova Z, Trebaticka J. Markers of oxidative stress and neuroprogression in depression disorder. Oxid Med Cell Longev. 2015;2015:898393.

Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol. 2008;11:851–6.

Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:201–17.

Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–7.

Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–86.

Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? International journal of cardiology. 2006;108(3):410-1.

Peacock F, Morris DL, Anwaruddin S, Christenson RH, Collinson PO, Goodacre SW, et al. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. American heart journal. 2006;152(2):253-62.

Dahiya K, Aggarwal K, Seth S, Singh V, Sharma TK. Type 2 diabetes mellitus without vascular complications and ischemia modified albumin. Clin Lab. 2010;56:187-90.

Unal K, Topcuoglu C, Cingi Yirun C. Serum ischemia modified albumin (IMA) levels of patients with bipolar disorder in remission and healthy controls. Biomedical Research. 2018; 29(12):2672-5.

Tunç S, Atagün Mİ, Neşelioğlu S, Bilgin YY, Başbuğ HS, Erel Ö. Ischemia-modified albumin: a unique marker of global metabolic risk in schizophrenia and mood disorders. Psychiatry and Clinical Psychopharmacology. 2019;29(2):123-9.






Research Article

How to Cite

Karaaslan Özgül, Hacımusalar Y, Amuk Özge C, Bal C. Evaluation of ischemia modified albumin levels in major depression patients. J Surg Med [Internet]. 2019 Aug. 1 [cited 2022 Sep. 28];3(8):557-60. Available from: https://jsurgmed.com/article/view/598200